Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Present with chronic plaque psoriasis based on a confirmed diagnosis of chronic psoriasis vulgaris for at least 6 months prior to randomization~* At least 10% Body Surface Area (BSA) of Psoriasis at screening and at randomization~* Static Physician Global Assessment (sPGA) score of at least 3 AND Psoriasis Area and Severity Index (PASI) score of at least 12 at screening and at randomization~* Candidate for phototherapy and/or systemic therapy~* Men must agree to use a reliable method of birth control during the study~* Women must agree to use birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment~Exclusion Criteria:~* Pustular, erythrodermic, and/or guttate forms of psoriasis~* History of drug-induced psoriasis~* Clinically significant flare of psoriasis during the 12 weeks prior to randomization~* Concurrent or recent use of any biologic agent~* Received systemic psoriasis therapy \[such as psoralen and ultraviolet A (PUVA) light therapy\] or phototherapy within the previous 4 weeks; or had topical psoriasis treatment within the previous 2 weeks prior to randomization~* Cannot avoid excessive sun exposure or use of tanning booths for at least 4 weeks prior to randomization and during the study~* Have participated in any study with interleukin-17 (IL-17) antagonists, including Ixekizumab~* Serious disorder or illness other than plaque psoriasis~* Serious infection within the last 3 months~* Breastfeeding or nursing (lactating) women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 80 mg Ixekizumab Auto-Injector (Type: EXPERIMENTAL): Ixekizumab administered by two 80 milligram (mg) subcutaneous (SC) injections at Week 0, then one 80 mg SC injection every 2 weeks (Q2W) at week 2, 4, 6, 8 and 10. Starting from Week 12, 80 mg Ixekizumab Prefilled Syringe was administered by one 80 mg SC injection every 4 weeks (Q4W).
- 80 mg Ixekizumab Prefilled Syringe (Type: EXPERIMENTAL): Ixekizumab administered by two 80 mg SC injections at Week 0, then one 80 mg SC injection Q2W at week 2, 4, 6, 8 and 10. Starting from Week 12, 80 mg Ixekizumab Prefilled Syringe was administered by one 80 mg SC injection Q4W.

Based on this trial design, predict the completion outcome and termination type (if applicable).